evocatal
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | - | 2.0m | 1.3m | 1.2m | 1.6m | - | 1.4m |
% growth | - | - | (36 %) | (7 %) | 33 % | - | - |
Profit | (3.2m) | (<1m) | (<1m) | <1m | <1m | (<1m) | - |
% profit margin | - | (21 %) | (58 %) | 22 % | 10 % | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Seed | |
N/A | Seed | ||
N/A | €2.0m | Series B | |
N/A | €3.5m | Series B | |
Total Funding | CAD8.3m |
Related Content
Recent News about evocatal
EditEvoxx Technologies GmbH, now a part of Advanced Enzyme Technologies Limited, is a specialty biotech company focused on the research, development, and manufacturing of enzymes and probiotics. The company serves a diverse range of clients including healthcare providers, agricultural businesses, and industrial manufacturers. Operating in the industrial biotechnology market, Evoxx Technologies aims to provide side effect-free healthcare solutions, enhance animal nutrition for farmers, and replace traditional industrial processes with enzyme-based alternatives. The business model revolves around the development and commercialization of proprietary enzyme and probiotic products, generating revenue through product sales and licensing agreements. Evoxx Technologies leverages its expertise in biotechnology to deliver innovative solutions that meet the evolving needs of its clients.
Keywords: enzymes, probiotics, healthcare, agriculture, industrial biotechnology, enzyme-based processes, animal nutrition, proprietary products, biotech solutions, Advanced Enzyme Technologies.